Total amount: € 0,00
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index
Morelli M. 1, 2, Mocciaro R. 1, Venturella R. 1, Albano A. 1, Sacchinelli A. 1, Zullo F. 1, 2
1 Department of Obstetrics and Gynecology, “Magna Graecia” University, Catanzaro, Italy;
2 Unit of Gynecologic Oncology, “Tommaso Campanella” Cancer Center of Germaneto, Catanzaro, Italy
AIM: Aim of the study was to validate the Hyaluronic acid–Chondroitin sulfate (HA-CS) as ex adiuvantibus criteria to identified patients with urgency symptoms related to interstitial cystitis/painful bladder syndrome (IC/PBS) and to obtained a population of patients with pure stress urinary incontinence.
METHODS: We retrospectively analysed clinical data of 17 patients with clinical suspect of IC/PBS, which received intravescical HA-CS to reduce pelvic pain and urgency symptoms waiting for surgical treatment for stress urinary incontinence. The main outcomes were reduction of urinary frequency, urgency, and bladder pain.
RESULTS: Compared to baseline, a significant decrease in pain, urgency and frequency were observed. Of the 17 patients, 82.3% reported resolution of pain and urge symptoms and in patients with persistence of urge symptoms the urodynamic assessment showed an overactive bladder syndrome (OAB).
CONCLUSION: HA-CS treatment induces an improvement in pain and urgency symptoms in patients with IC⁄PBS that referred also stress urinary incontinence. Therefore, HA-CS treatment could be use as clinical adjunctive parameter to select patients with pure stress urinary incontinence.